

What's New in GI Pharmacology Course
Pennsylvania Convention Center
Philadelphia, Pennsylvania
October 5, 2018

Course Directors:

Brooks D. Cash, MD, FACG

William D. Chey, MD, FACG

Up to 3.25 hours of CME & 3.25 MOC points

- 1:45 pm **Welcome and Introductions**
Brooks D. Cash, MD, FACG, and William D. Chey, MD, FACG
- 1:50 pm **Functional Dyspepsia: Current Pharmacologic Approaches**
William D. Chey, MD, FACG
Identify the epidemiology, diagnostic processes, and best practices for the management of functional dyspepsia.
- 2:10 pm **Contemporary Review of PPI Therapy: What You and Your Patients Need to Know**
Stuart J. Spechler, MD, FACG
Discuss the clinical evidence for the use of PPIs in a variety of clinical scenarios, and review current evidence regarding short- and long-term safety of PPIs.
- 2:30 pm **Approach to Symptomatic Diverticular Disease**
Lisa L. Strate, MD, MPH, FACG
Describe the various presentations of symptomatic diverticular disease, and review current therapeutic approaches.
- 2:50 pm **Antibiotic Prophylaxis for the Gastroenterologist**
Michelle A. Anderson, MD
Explain the evidence for and against the application of antibiotic prophylaxis in patients with gastrointestinal diseases or undergoing endoscopic procedures.
- 3:10 pm **Q & A**
- 3:25 pm **Break**
- 3:40 pm **Pharmacologic Approach to Chronic Constipation and IBS-C**
Brooks D. Cash, MD, FACG
Define current and emerging pharmacologic treatment options for constipation, including chronic idiopathic constipation, opioid-induced constipation, and IBS-C.
- 4:00 pm **Medical Management of Fatty Liver Disease**
Phillip K. Henderson, DO
Discuss the issues and interventions currently available for the management of patients with fatty liver disease, with a focus on available pharmacologic approaches.
- 4:20 pm **Chemoprevention for Gastrointestinal Malignancies**
John M. Inadomi, MD, FACG
Identify the evidence for and against chemoprevention for malignancies of the gastrointestinal tract and provide recommendations for appropriate use.

- 4:40 pm **Personalized IBD Management: Best Practices for Therapeutic Drug Monitoring and for Managing Treatment Failures**
David T. Rubin, MD, FACG
Outline therapeutic drug monitoring in IBD patients, and how to optimize immunosuppressive drug therapy with regard to adjusting therapy in class or switching classes of biologics.
- 5:00 pm **Q & A**
- 5:15 pm **Course Adjourns**